Shanghai IxCell Biotechnology

IxCell Biotechnology is a Shanghai-based biotechnology company focused on the development of universal, off-the-shelf cell therapies using induced pluripotent stem cell (iPSC) technology. The company leverages its proprietary platform to differentiate iPSCs into various therapeutic cell types, including natural killer (NK) cells and mesenchymal stem cells (MSCs), aimed at treating cancer, autoimmune diseases, and regenerative medicine indications. Their lead programs, such as IXC-101, target high-unmet-need areas like osteoarthritis and solid tumors. IxCell aims to solve the scalability and cost challenges associated with traditional autologous cell therapies through standardized manufacturing processes. The company is supported by a strong syndicate of investors, including Qiming Venture Partners and Lilly Asia Ventures.